Cover Image
市場調查報告書

Melinta Therapeutics, Inc的產品平台分析

Melinta Therapeutics, Inc - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 321337
出版日期 內容資訊 英文 50 Pages
訂單完成後即時交付
價格
Back to Top
Melinta Therapeutics, Inc的產品平台分析 Melinta Therapeutics, Inc - Product Pipeline Review - 2016
出版日期: 2016年02月29日 內容資訊: 英文 50 Pages
簡介

Melinta Therapeutics, Inc是總公司設置於美國的生物製藥企業,著重於開發新的抗菌劑。處於第三代臨床實驗中的抗菌劑delafloxacin,是開發為急性細菌性皮膚及皮膚組織感染疾病,單純性淋病的治療藥。這些產品是為了克服抗藥性問題而改變的。

本報告提供Melinta Therapeutics, Inc 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Melinta Therapeutics, Inc 基本資料

  • Melinta Therapeutics, Inc 概要
  • 主要資訊
  • 企業資料

Melinta Therapeutics, Inc :R&D概要

  • 主要的治療範圍

Melinta Therapeutics, Inc :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Melinta Therapeutics, Inc :開發中產品概況

  • 後期階段產品開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式
  • ■Melinta Therapeutics, Inc :藥物簡介
  • delafloxacin
  • radezolid
  • RX-02
  • RX-04
  • RX-05
  • RXP-792
  • RXP-873
  • RXP-763
  • RXP-766
  • RXP-770
  • RXP-793
  • RXP-808

Melinta Therapeutics, Inc :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Melinta Therapeutics, Inc :最新的開發平台資訊

Melinta Therapeutics, Inc :中止開發的計劃

Melinta Therapeutics, Inc :企業理念

Melinta Therapeutics, Inc :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07975CDB

Summary

Global Markets Direct's, 'Melinta Therapeutics, Inc - Product Pipeline Review - 2016', provides an overview of the Melinta Therapeutics, Inc's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Melinta Therapeutics, Inc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Melinta Therapeutics, Inc
  • The report provides overview of Melinta Therapeutics, Inc including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Melinta Therapeutics, Inc's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Melinta Therapeutics, Inc's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Melinta Therapeutics, Inc's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Melinta Therapeutics, Inc
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Melinta Therapeutics, Inc's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Melinta Therapeutics, Inc Snapshot
    • Melinta Therapeutics, Inc Overview
    • Key Information
    • Key Facts
  • Melinta Therapeutics, Inc - Research and Development Overview
    • Key Therapeutic Areas
  • Melinta Therapeutics, Inc - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Melinta Therapeutics, Inc - Pipeline Products Glance
    • Melinta Therapeutics, Inc - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Melinta Therapeutics, Inc - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Melinta Therapeutics, Inc - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Melinta Therapeutics, Inc - Drug Profiles
    • delafloxacin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • radezolid
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RX-02
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RX-04
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RX-05
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RXP-792
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RXP-873
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RXP-763
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RXP-766
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RXP-770
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RXP-793
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RXP-808
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Melinta Therapeutics, Inc - Pipeline Analysis
    • Melinta Therapeutics, Inc - Pipeline Products by Target
    • Melinta Therapeutics, Inc - Pipeline Products by Route of Administration
    • Melinta Therapeutics, Inc - Pipeline Products by Molecule Type
    • Melinta Therapeutics, Inc - Pipeline Products by Mechanism of Action
  • Melinta Therapeutics, Inc - Recent Pipeline Updates
  • Melinta Therapeutics, Inc - Dormant Projects
  • Melinta Therapeutics, Inc - Company Statement
  • Melinta Therapeutics, Inc - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Melinta Therapeutics, Inc, Key Information
  • Melinta Therapeutics, Inc, Key Facts
  • Melinta Therapeutics, Inc - Pipeline by Indication, 2016
  • Melinta Therapeutics, Inc - Pipeline by Stage of Development, 2016
  • Melinta Therapeutics, Inc - Monotherapy Products in Pipeline, 2016
  • Melinta Therapeutics, Inc - Phase III, 2016
  • Melinta Therapeutics, Inc - Phase II, 2016
  • Melinta Therapeutics, Inc - Preclinical, 2016
  • Melinta Therapeutics, Inc - Discovery, 2016
  • Melinta Therapeutics, Inc - Pipeline by Target, 2016
  • Melinta Therapeutics, Inc - Pipeline by Route of Administration, 2016
  • Melinta Therapeutics, Inc - Pipeline by Molecule Type, 2016
  • Melinta Therapeutics, Inc - Pipeline Products by Mechanism of Action, 2016
  • Melinta Therapeutics, Inc - Recent Pipeline Updates, 2016
  • Melinta Therapeutics, Inc - Dormant Developmental Projects,2016
  • Melinta Therapeutics, Inc, Other Locations

List of Figures

  • Melinta Therapeutics, Inc - Pipeline by Top 10 Indication, 2016
  • Melinta Therapeutics, Inc - Pipeline by Stage of Development, 2016
  • Melinta Therapeutics, Inc - Monotherapy Products in Pipeline, 2016
  • Melinta Therapeutics, Inc - Pipeline by Target, 2016
  • Melinta Therapeutics, Inc - Pipeline by Route of Administration, 2016
  • Melinta Therapeutics, Inc - Pipeline by Molecule Type, 2016
  • Melinta Therapeutics, Inc - Pipeline Products by Mechanism of Action, 2016
Back to Top